|
nasdaq:clsn
|
100110
|
Apr 21st, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 20th, 2024 11:13PM
|
Apr 20th, 2024 11:13PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 20th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 19th, 2024 11:11PM
|
Apr 20th, 2024 04:46PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 19th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 18th, 2024 11:18PM
|
Apr 18th, 2024 11:18PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 18th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 17th, 2024 11:17PM
|
Apr 18th, 2024 06:06PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 17th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 16th, 2024 11:07PM
|
Apr 17th, 2024 02:30PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 16th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 15th, 2024 11:02PM
|
Apr 16th, 2024 10:47AM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 15th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 14th, 2024 10:59PM
|
Apr 15th, 2024 04:28PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 14th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 13th, 2024 10:48PM
|
Apr 13th, 2024 10:48PM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 13th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 12th, 2024 10:39PM
|
Apr 13th, 2024 11:14AM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|
|
nasdaq:clsn
|
100110
|
Apr 12th, 2024 12:00AM
|
Celsion Corporation
|
1.4K
|
25.00
|
Open
|
|
Apr 11th, 2024 10:43PM
|
Apr 12th, 2024 08:09AM
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Open
|
|
Open
|
|
|
|
US
|
|
|
Celsion
|
|
|